Ocugen preps dry eye disease drug for phase 3

Dry eye disease affects an estimated 16 million Americans. (Laitr Keiows)

Eye disease specialist Ocugen remains on course to have two drugs in late-stage testing before the end of the year as its dry eye disease candidate OCU310 clears a phase 2 trial.

The proof-of-concept study showed that OCU310—a combination of already-approved drugs brimonidine tartrate and loteprednol etabonate—improved various symptoms of dry eye disease compared to placebo over 12 weeks and hit its primary target of tolerability, according to the Pennsylvania biotech.

The trial wasn’t powered to show efficacy but showed patients taking the twice-daily eyedrop formulation reported improvements in the frequency and severity of eye dryness and irritation using a questionnaire (the SANDE scale) compared to placebo.


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

If phase 3 trials (of an improved nanoemulsion formulation) are positive, OCU310 could provide Ocugen with a rapid route to a commercial product, as it is based on two established drugs with a long history of ophthalmic use. That “significantly derisks OCU310 from a product safety and regulatory … standpoint,” the company said in a release.

It’s estimated that as many as 16 million Americans have been diagnosed with dry eye disease, an itchy, uncomfortable and disruptive condition that is the top reason people visit their ophthalmologist. For years, the only treatment options were artificial tears, providing temporary relief at best.

There are however two approved drugs for dry eye disease—Allergan’s Restasis (cyclosporine) and Shire’s recently approved LFA-1 antagonist Xiidra (lifitegrast)—although additional treatment options are needed. Ocugen reckons its candidate will have a more rapid onset of action, improved tolerability, and a greater impact on symptoms than currently marketed rivals.

“We believe OCU310 can provide significant benefit to those suffering from dry eye disease, and we look forward to presenting the full results at a future academic meeting, and discussing with the FDA in the coming months," commented Daniel Jorgensen, M.D., Ocugen’s chief medical officer.

The positive trial means that OCU310 could join the biotech’s brimonidine-only nanoemulsion OCU300 for ocular graft-versus-host disease in phase 3 before the end of 2018. Ocugen says it remains on track to advance OCU310 into phase 3 studies in the third quarter of 2018

Eyecare market research firm Market Scope estimated in January that new drugs will help drive the dry eye treatment market from a value of $3.7 billion in 2017 to nearly $4.9 billion in 2022, thanks to a series of new product introductions including Allergan’s TrueTear device for increasing tear production.

Suggested Articles

J&J's DePuy Synthes division has launched a new fixation system to expand treatment options for patients with frail bones in the neck and upper back.

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Tokyo-based Heartseed has raised 2.8 billion yen, or about $26 million U.S., to help develop its stem cell-based treatment for heart failure.